Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

Ascletis completes enrollment in US phase IIa study of small molecule oral GLP-1R agonist, ASC30 to treat obesity: Hong Kong Wednesday, August 6, 2025, 10:00 Hrs [IST] Ascletis Ph ...

Supergut, a leader in gut-health innovation, announced the launch of three new flavors of its GLP-1 Booster: Blood Orange, ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...

Jefferies upgradeed Gland Pharma to hold, as it believe earnings downcycle for the company is behind and in next 1-2 years can benefit from the generic GLP driven tailwinds ...

Linda Yaccarino, the former X CEO who left the social media company in the wake of yet another Elon Musk controversy, has ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Former X CEO Linda Yaccarino said Tuesday she has taken on a new role leading a digital health platform, less than a month ...

The Trump administration is planning to pilot covering weight loss drugs. A longtime healthcare exec moves to a strategic advisory role at General Catalyst.

Dale Forrest said he wanted to lose weight "naturally" — and a year after starting his weight loss journey, he “can now play ...